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Abstract 
Background: Cancer, a major cause of mortality worldwide, is a group of diseases distinguished by uncontrolled 
growth and expansion of abnormal cells. According to American Cancer Society, melanoma, a kind of skin cancer, is 
one of the most prevalent cancers. The side effects of chemical treatment developed more demands on natural 
products. Flavonoids, polyphenol compounds, with anticancer and antioxidant activity attracted more attention to 
themselves. 
Materials and Methods: Through this investigation the effect of myricetin on cell proliferation was determined by 
MTT (Methylthiazolyl diphenyl-tetrazolium bromide) assay. A375 cell lines were seeded in a 96 wells plate and were 
exposed to different concentrations of myricetin (10, 15, 20, 40, 60, 80, and 100µΜ). After considered times, the 
MTT solution was added, then the viability of cells was detected by measuring the absorbance on 570 and 630 nm. 
Results: Our finding showed that low concentration of myricetin (up to 25µM) has no toxicity effect. Also the 
result confirmed the IC50 of myricetin on melanoma cells for three ordered period (24, 48, 72 hours) as following: 
50, 40, 35µΜ, respectively. 
Conclusion: According to this research, myricetin has anti-proliferative effect on melanoma cells, which can be used 
as a therapeutic agent. We hope that this study could be used as a mile stone in future researches to acquire 
confirmative results. 
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Cancer as a leading cause of death in most countries, 
especially in less developed countries is growing 
worldwide. The approval of mechanical lifestyle, poor 
diet, less activity, smoking and reproductive changes 
have increased the cancer burden globally
1
. Among the 
list of common cancers reported by the American Cancer 
Society, melanoma, a kind of skin cancer, due to new 
lifestyles allocated high rate of mortality to itself
2
. 
The toxicity of current chemotherapeutics put all of 
efforts toward new anticancer drugs with greater efficacy 
and fewer side effects. Among natural compounds, low 
molecular weight product, flavonoids, rich in seeds, 
vegetables, and citrus fruits, attracted more attention 
according to their impressive pharmacological properties 
including antibacterial, antioxidant, antiangiogenic, 
anticancer and antiallergic activities
3
.  
Chemically they are polyphenol with a phenyl 
benzopyrone structure (C6- C3-C6), on the basis of 
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saturation level, C- ring substitution pattern and opening 
of the central pyron ring classified into different groups 
of flavonoids
4,5
 (Figure 1). There is a relationship 
between the activity of flavonoids and their structure, so 
myricetin based on the presence of an ortho-hydroxyl 
groups, a C2-C3 double bond in the C- ring is considered 




The role of myricetin to promote apoptosis, inhibition of 
signaling pathway, and cell cycle block is distinguished. 
Some studies showed that myricetin inhibited the 
proliferation of GC HGC-27 and SGC 7901 cells invivo 
and invitro
8
. However the function of myricetin in 
melanoma cells is not determined, in this study we 
determined the effect of myricetin on proliferation and 
viability of A375 cells. 
As myricetin has presented the anti-inflammatory 
activity, a research exhibited that this flavonoid could 
suppress the activation of Akt, NF-κB pathway that lead 
to the reduction of TNF-α-stimulated inflammatory 
mediator
9
. Another study showed that myricetin can be 
used as a potent inhibitor of purine synthesis pathway 
which is crucial for cancer development
10
. Beside these 
efficacies of myricetin another potency of myricetin is 





Myricetin, MTT (Methylthiazolyl diphenyl-tetrazolium 
bromide) powder was purchased from sigma Aldrich. 
A375 cell line was prepared from pasture institution. FBS 
(Fetal bovine serum), PBS (phosphate – buffered saline) 
tablet, penicillin-streptomycin, trypsin-EDTA were 
obtained from Invitrogen. Culture media (DMEM high 
glucose) was obtained from Biosera.  
A375 cells were cultured in DMEM high glucose, 
containing 10% (v/v) FBS and 1% penicillin-
streptomycin. The cells were incubated at 37˚С
 
in a 
humidified atmosphere of 5% CO2
. 
Confluent cultures of 
melanoma cells were rinsed in phosphate- buffered saline 
(PBS) and removed from the flask using 0.25% 
trypsin/EDTA, neutralized with FBS and the cell 
suspension were prepared. 
To find the doubling time of melanoma cells, the 8000 
cells were placed on each well in a 96 wells plate. During 
one week in different periods of time (24, 32, 48, 56, 72, 
76, 80, 96, 100, and 122h) the cells were counted and the 
data were recorded. The experiments were done 
quadruplicate. Three 96 well plate for three period of 
time (24, 48, 72 hours) were chosen. The cells were 
placed at a density of 8000 cell/well with culture media 
for an overnight to attach the plate.  
Cell viability was detected by use of micro culture 
tetrazolium technique (MTT). This quantitative measure 
provides the number of viable cells by determining the 
amount of formazan crystals produced by metabolic 
activity in treated versus control cells. After 24 h, the 
media was replaced with different concentrations of 
myricetin as following: negative control, 0.1% ethanol 
control, 10µM, 15 µM, 20 µM, 40 µM, 60 µM, 80 µM, 
100 µM, and DMSO 30% as positive control. After 
incubation in determined time (24, 48, 72 hours) the 
media was removed, new media along with MTT reagent 
in PBS (5 mg/ml) was added to each well. The plates 
were incubated for 4 hours in a humidified atmosphere of 
5% of co2 at 37˚C. After removing the media, DMSO 
was added and the absorbance was measured at 570 nm 
relative to 630 nm. All experiments were done 5 times. 
Statistical analysis was performed using PRISM 
software. Differences between the control and treated 
group were analyzed by mean±SD using one-way 
ANOVA test with considering significant at p<0.05 and 
p<0.0001. This study is investigated according to the 
Helsinki declaration approved by our regional institution 
number: IR.QUMS.REC.1394.155 Qazvin University of 
medical science. 
Results 
After recording the data in Excel software, the result 
showed that the doubling time of melanoma (A375) cells 
was about 17 hour (Figure 3). To ascertain the inhibitory 
effect of myricetin on melanoma cells, A375 cells were 
treated with different concentrations in three period of 
time (24, 48, and 72 Hours). As shown in Fig4, the more 
concentration of myricetin, the more mortality of cells 
was seen, so that in high concentration like 100µM, 
almost all cells were inhibited. Also Fig5 verified that 
low concentration (up to 25 µM) has no significantly 
cytotoxic effect and the IC50 (50% inhibitory 
concentration) for 24 h, 48 h, and 72h was 50 µM, 40 µM  
and 35 µM respectively. 
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Discussion 
Myricetin as a kind of flavonoid, widely spread in 
vegetables and fruits, has multiple biological effects. In 
the present study our primary result indicated that 
myricetin could inhibit cell proliferation. We determined 
that the inhibitory effect (IC50) of Myricetin on 
melanoma cells (A375) for 24, 48, and 72 h was 50, 40, 
and 35µM, respectively. 
Although melanoma displays less than 10% of skin 
cancer, it is accountable for more than 75% of skin 
cancer- related death
12
. Over the past decade, according 
to the significant acceleration of cancer, substantial 
compounds include flavonoids of human diet raised more 
demand
13
. Studies have suggested that myricetin could 
inhibit tumor growth
14
, and block signal transduction
15
. 
Several studies investigated that flavonoids could be 






A research demonstrated that structurally related 













Figure 3. Cell counting curve. 
 
y = 0.0167x + 3.5204 
























Figure 4. After treatment with different concentrations of myricetin. 
The groups were A, B, C, D, E, F, G, H, and I, with different 
concentrations as: control, 0.1% ethanol, 10, 15, 20, 40, 60, 80, 
and100µΜ myricetin respectively. 
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Another study showed that Quericetin, a kind of 
flavonoid, can motivate apoptosis in tumor cells 
containing K 562, Molt-4, gastric and lung cells
19
. 
Since there is a relationship between the structure and 
function of flavonoids, three hydroxyl group in B-ring of 
myricetin, can modulate its inhibitory effect and exhibit 
brilliant anticancer, antioxidant, anti-inflammatory 
properties
20
 (Figure 2). Myricetin has been investigated 





. Another study determined that the 
concentration of myricetin up to 25µΜ has no 
significantly effect on HaCaT cell viability
9
.  
Our finding in this manuscript showed that myricetin 
greatly decreased melanoma cell viability (Figure 5). Our 
result verified that low concentration of myricetin had no 
cytotoxicity effect on cells, but high dosage of myricetin 
can cause cell mortality (Figure 4). We also detected that 
myricetin IC50 was 50µM, 40 µM, and 35 µM in order 
for 24, 48, and 72h (Figure 5). 
Another research has demonstrated that myricetin can 
inhibit different signaling pathway such as PI3 kinase/ 
Akt5
23
. Some studies have shown that myricetin can 




This work once again demonstrated the importance of 
these natural products as the potential chemopreventive 
agents. 
Conclusion 
This work in approval of other researches acknowledged 
the inhibitory effect of myricetin and showed that 
myricetin in low concentration (up to 25 µM) had no 
toxicity effect; also the inhibitory effect (IC50) of 
myricetin for 24, 48, and 72h was respectively 50, 40, 
and 35 µM. These preliminary results showed that MTT 
 
 
Figure 5. Myricetin inhibits proliferation of melanoma cells. A, B, and C were respectively 24, 48, and72 hour post treatment with myricetin. Data 
were presented as the mean ± SD of 5 times experiments.  
(*P<0.05, ***P< 0.0001) versus control group. 
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assay could be used as a primary technique to determine 
the cytotoxicity effect of drugs and to evaluate the 
resistance of cells to different agents. 
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